25% off STAT+ and February's top stories

Get 25% off an annual STAT+ subscription and read more of our award-winning journalism.

Log In  STAT+ Check out last month's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year. Why Novartis is going to walk away from its acquisition of MorphoSys By Adam Feuerstein READ NOW A junior scientist. A prominent oncologist. Now, a clash at MD Anderson over who gets research credit By Angus Chen and Jonathan Wosen READ NOW Gaming Amylyx stock reactions to the next ALS drug test, and a chat with CRISPR's CEO about a new investor By Adam Feuerstein READ NOW Subscribe to STAT+ Enjoy discounts on STAT Reports and events, free access to premium data tools, and daily coverage of the life sciences. Subscribe BUSINESS Government warns Medicare Advantage insurers not to deny care based on AI HEALTH TECH AI can speed up drug discovery but don't expect it to cure cancer, yet ADAM'S TAKE A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys ADAM'S TAKE Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio PHARMA Liver disease MASH is next target for obesity drugs in development EXCLUSIVE AI therapy and ICU training: A first look at health apps for Apple Vision Pro MATT'S TAKE Novo's Catalent deal is great for GLP-1s. But what about drug manufacturing? SUBSCRIBE STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us